$ News

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

How Genmab’s US$2.5 Billion Merus Deal Financing Could Impact Genmab (CPSE:GMAB) Investors

Merus N.V. (MRUS): A Bull Case Theory

Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes

Assessing Merus (MRUS) Valuation Following Recent Share Price Surge

Rare NRG1 Fusion Market Research Report 2025-2035 | Growth Accelerates on Rising Cancer Awareness and Advances in Molecular Testing and Targeted Therapies

Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes

Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility

Genmab To Offer $1.5B Of Senior Secured Notes Due 2032 And $1B Of Senior Unsecured Notes Due 2033, The Company Also Launched The Syndication Of A New $2B Senior Secured Term Loan In Addition To A $1B Senior Secured Term Loan Facility And $500M Senior Secured Revolving Credit Facility To Finance The Merus Acquisition

Genmab Announces Financial Results for the Nine Months of 2025

Merus N.V. (MRUS) Presents at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Slideshow

Merus (MRUS): Assessing Valuation After Recent 38% Stock Gain

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.

Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Merus (MRUS): Assessing Valuation After Rapid Share Price Gains

Merus (MRUS) Gains Validation With Zenocutuzumab Approval, Barclays Sees Growth Potential

Merus (MRUS) Soars to New High on Genmab Merger at 41% Premium

EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction